Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears

被引:182
作者
Szarewski, Anne [1 ]
Ambroisine, Laurence [1 ]
Cadman, Louise [1 ]
Austin, Janet [1 ]
Ho, Linda [1 ]
Terry, George [1 ]
Liddle, Stuart [2 ]
Dina, Roberto [3 ]
McCarthy, Julie [5 ]
Buckley, Hilary [6 ]
Bergeron, Christine [7 ]
Soutter, Pat [4 ]
Lyons, Deirdre [8 ]
Cuzick, Jack [1 ]
机构
[1] Wolfson Inst Prevent Med, Canc Res UK Ctr Epidemiol Math & Stat, London EC1M 6BQ, England
[2] Doctors Lab, London, England
[3] Hammersmith & Queen Charlottes & Chelsea Hosp, Dept Cytopathol, London, England
[4] Hammersmith & Queen Charlottes & Chelsea Hosp, Dept Gynaecol, London, England
[5] St Marys Hosp, Dept Cytopathol, London, England
[6] St Marys Hosp, Dept Pathol, Manchester M13 0JH, Lancs, England
[7] Lab Pasteur Cerba, Cergy Pontoise, France
[8] St Marys Hosp, Dept Gynaecol, London, England
关键词
D O I
10.1158/1055-9965.EPI-08-0508
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The detection of high-risk human papillomavirus (HPV) DNA provides higher sensitivity but lower specificity than cytology for the identification of high-grade cervical intraepithelial neoplasia (CIN). This study compared the sensitivity and specificity of several adjunctive tests for the detection of high-grade CIN in a population referred to colposcopy because of abnormal cytology. Methods: 953 women participated in the study. Up to seven tests were carried out on a liquid PreservCyt sample: Hybrid Capture II (Digene), Amplicor (Roche), PreTect HPV-Proofer (NorChip),APTIMA HPV assay (Gen-Probe), Linear Array (Roche), Clinical-Arrays (Genomica), and CINtec p16(INK4a) Cytology (mtm Laboratories) immunocytochemistry. Sensitivity, specificity, and positive predictive value (PPV) were based on the worst histology seen on either the biopsy or the treatment specimen after central review. Results: 273 (28.6%) women had high-grade disease (CIN2+) on worst histology, with 193 (20.2%) having CIN3+. For the detection of CIN2+, Hybrid Capture II had a sensitivity of 99.6%, specificity of 28.4%, and PPV of 36.1%. Amplicor had a sensitivity of 98.9%, specificity of 21.7%, and PPV of 33.5%. PreTect HPV-Proofer had a sensitivity of 73.6%, specificity of 73.1%, and PPV of 52.0%. APTIMA had a sensitivity of 95.2%, specificity of 42.2%, and PPV of 39.9%. CINtec p16(INK4a), Cytology had a sensitivity of 83.0%, specificity of 68.7%, and PPV of 52.3%. Linear Array had a sensitivity of 98.2%, specificity of 32.8%, and PPV of 37.7%. Clinical-Arrays had a sensitivity of 80.9%, specificity of 37.1%, and PPV of 33.0%. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3033-42)
引用
收藏
页码:3033 / 3042
页数:10
相关论文
共 24 条
[1]   Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru [J].
Almonte, Maribel ;
Ferreccio, Catterina ;
Winkler, Jennifer L. ;
Cuzick, Jack ;
Tsu, Vivien ;
Robles, Sylvia ;
Takahashi, Rina ;
Sasieni, Peter .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (04) :796-802
[2]   Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial [J].
Bulkmans, N. W. J. ;
Berkhof, J. ;
Rozendaal, L. ;
van Kemenade, F. J. ;
Boeke, A. J. P. ;
Bulk, S. ;
Voorhorst, F. J. ;
Verheijen, R. H. M. ;
Groningen, Kvan ;
Boon, M. E. ;
Ruitinga, W. ;
van Ballegooijen, M. ;
Snijders, P. J. F. ;
Meijer, C. J. L. M. .
LANCET, 2007, 370 (9601) :1764-1772
[3]   Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening [J].
Bulkmans, NWJ ;
Rozendaal, L ;
Voorhorst, FJ ;
Snijders, PJF ;
Meijer, CJLM .
BRITISH JOURNAL OF CANCER, 2005, 92 (09) :1800-1802
[4]   Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease [J].
Carozzi, Francesca ;
Bisanzi, Simonetta ;
Sani, Cristina ;
Zappa, Marco ;
Cecchini, Silvia ;
Ciatto, Stefano ;
Confortini, Massimo .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (02) :364-369
[5]   Management of women who test positive for high-risk types of human papillomavirus: the HART study [J].
Cuzick, J ;
Szarewski, A ;
Cubie, H ;
Hulman, G ;
Kitchener, H ;
Luesley, D ;
McGoogan, E ;
Menon, U ;
Terry, G ;
Edwards, R ;
Brooks, C ;
Desai, M ;
Gie, C ;
Ho, L ;
Jacobs, I ;
Pickles, C ;
Sasieni, P .
LANCET, 2003, 362 (9399) :1871-1876
[6]   Overview of the European and North American studies on HPV testing in primary cervical cancer screening [J].
Cuzick, Jack ;
Clavel, Christine ;
Petry, Karl-Ulrich ;
Meijer, Chris J. L. M. ;
Hoyer, Heike ;
Ratnam, Samuel ;
Szarewski, Anne ;
Birembaut, Philippe ;
Kulasingam, Shalini ;
Sasieni, Peter ;
Iftner, Thomas .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (05) :1095-1101
[7]   Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear [J].
De Francesco, M. A. ;
Gargiulo, E. ;
Schreiber, C. ;
Ciravolo, G. ;
Salinaro, E. ;
Manca, N. .
JOURNAL OF VIROLOGICAL METHODS, 2008, 147 (01) :10-17
[8]   Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance [J].
Halfon, Philippe ;
Trepo, Elisabeth ;
Antoniotti, Gilles ;
Bernot, Catherine ;
Cart-Lamy, Philippe ;
Khiri, Hacene ;
Thibaud, Didier ;
Marron, Jean ;
Martineau, Agnes ;
Penaranda, Guillaume ;
Benmoura, Dominique ;
Blanc, Bernard .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (02) :313-316
[9]   p16INK4a immunoexpression:: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia [J].
Kalof, Alexandra N. ;
Cooper, Kumarasen .
ADVANCES IN ANATOMIC PATHOLOGY, 2006, 13 (04) :190-194
[10]   The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice [J].
Khan, MJ ;
Castle, PE ;
Lorincz, AT ;
Wacholder, S ;
Sherman, M ;
Scott, DR ;
Rush, BB ;
Glass, AG ;
Shiffman, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (14) :1072-1079